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Background: Combinations of inhaled long-acting bronchodilator therapies such as muscarinic
antagonists and b2-agonists may be more effective than monotherapy in the treatment of
chronic obstructive pulmonary disease (COPD).
Methods: This study was a 24-week, Phase III, multicenter, randomized, blinded, double-
dummy, parallel-group study of the once-daily, inhaled, fixed-dose combination of the long-
acting muscarinic antagonist umeclidinium bromide and the long-acting b2-agonist vilanterol
(UMEC/VI 62.5/25 mcg) versus tiotropium (TIO, 18 mcg). The primary endpoint was trough
forced expiratory volume in 1 s (FEV1) at Day 169. The secondary endpoint was weighted mean
FEV1 over 0e6 h post-dose at Day 168. For key endpoints, a step-down closed testing hierarchy
was applied to account for multiplicity. Other efficacy and safety endpoints were assessed.
Results: Statistically significant improvements in trough FEV1 at Day 169 (0.112 L, 95%confidence interval; COPD, chronic obstructive pulmonary disease; DPI, Dry powder inhaler; FEV1,
d; FP, fluticasone propionate; FVC, forced vital capacity; GOLD, Global initiative for Obstructive Lung
alth-related quality of life; ICS, inhaled corticosteroids; IEC, Independent Ethics Committee; IRB,
t-to-treat; LABA, long-acting b2-agonist; LAMA, long-acting muscarinic antagonist; LRTI, lower res-
ares; MMRM, mixed models repeated measures; OR, odds ratio; PDE4, phosphodiesterase 4; QoL,
vent; SD, standard deviation; SE, standard error; SGRQ, St George’s Respiratory Questionnaire; TIO,
vilanterol; WM, weighted mean.
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Efficacy and safety of umeclidinium/vilanterol 1753confidence interval [CI]: 0.081, 0.144; p < 0.001) and weighted mean FEV1 over 0e6 h post-
dose at Day 168 (0.105 L, 95% CI: 0.071, 0.140; p < 0.001) were observed for UMEC/VI versus
TIO. In addition UMEC/VI improved health-related quality of life, and reduced requirement for
the use of rescue medication compared with TIO. The incidence of adverse events was similar
between treatment groups.
Conclusions: UMEC/VI was associated with statistically significant and clinically meaningful im-
provements in lung function versus TIO. UMEC/VI was well tolerated. UMEC/VI 62.5/25 mcg
could provide an effective new treatment option for patients with moderate-to-very severe
COPD.
Clinical trial registration: ClinicalTrials.gov: NCT01777334.
ª 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
The pharmacological management of stable chronic
obstructive pulmonary disease (COPD) primarily aims to
improve symptoms and quality of life (QoL), optimize lung
function, and reduce exacerbations. Inhaled bronchodila-
tors such as muscarinic antagonists and b2-adrenoceptor
agonists are central to this approach [1,2]. Muscarinic
antagonists block acetylcholine-mediated broncho-
constriction by binding to M3 receptors in airway smooth
muscle [3]. In contrast, b2-agonists induce smooth muscle
relaxation by stimulating b2-adrenoceptors, leading to
increased levels of cyclic adenosine monophosphate and
reducing bronchoconstriction [2]. These distinct and com-
plementary mechanisms of action provide the opportunity
to develop combination bronchodilator therapies that may
further improve treatment efficacy in patients with COPD
and improve adherence to treatment. Combination thera-
pies may also lower the risk of side effects compared with
increasing the dose of a single agent in patients with
COPD [2,4].
Clinical studies of long-acting muscarinic antagonists
(LAMA) combined with long-acting b2-agonists (LABA) in
patients with COPD support this rationale and have shown
greater improvements in lung function compared with
monotherapies [5e7]. In addition, once-daily treatment
regimens offer greater convenience for patients compared
with more frequent dosing schedules.
A fixed-dose combination of the inhaled LAMA,
umeclidinium bromide (UMEC), and the inhaled LABA,
vilanterol (VI), is approved in the US and EU for the long-
term, once-daily maintenance treatment of COPD. Studies
have demonstrated that UMEC and VI improve lung function
and are well tolerated in patients with COPD, both as a
fixed-dose combination and as monotherapies [8e11].
Two large, Phase III, randomized studies recently
reported that combination therapy with once-daily
UMEC/VI 62.5/25 mcg or UMEC/VI 125/25 mcg (delivering
55/22 mcg and 113/22 mcg, respectively) provided
statistically significant and clinically meaningful improve-
ments in lung function measures versus tiotropium bromide
(TIO [Boehringer Ingelheim], an approved COPD treatment)
in patients with COPD [12,13]. Here, we report the results
of a multicenter, Phase III, randomized study which aims to
provide further data on lung function outcomes and health-related QoL (HRQoL) in a larger population of patients
receiving UMEC/VI 62.5/25 mcg versus TIO 18 mcg.Materials and methods
Study design
This was a 24-week, Phase III, multicenter, randomized,
double-dummy, parallel-group study of once-daily
UMEC/VI 62.5/25 mcg versus once-daily TIO 18 mcg
(ClinicalTrials.gov: NCT01777334; GSK study number:
ZEP117115). The study was conducted at 71 centers in eight
countries (Bulgaria, Canada, Germany, Hungary, Romania,
Russia, Spain, and the United States). The study was
approved by the relevant local ethics review committees
(Supplementary File 1) and conducted in accordance with
the Declaration of Helsinki and Good Clinical Practice
guidelines.
Patients
Patients aged 40 years with moderate-to-very severe
COPD and an established clinical history of COPD as defined
by American Thoracic Society/European Respiratory Soci-
ety guidelines were eligible for enrollment [1]. Patients
were excluded if they were hospitalized for COPD or
pneumonia within 12 weeks prior to Visit 1. Full inclusion
and exclusion criteria are listed in Supplementary File 2.
All patients gave written, informed consent before study
participation.Treatment
Patients were randomized 1:1 to treatment with once-daily
UMEC/VI 62.5/25 mcg (delivering 55/22 mcg) via dry pow-
der inhaler (DPI, ELLIPTA DPI) or TIO 18 mcg (via Handi-
Haler) for 24 weeks. The randomization code was
generated using a GlaxoSmithKline validated computerized
system, RandAll version 2.5. Allocation of treatments was
controlled using RAMOS (Randomization and Medication
Ordering System, GlaxoSmithKline) and the link to the
randomization schedule was kept confidential from all
staff. Treatments were assigned by a dedicated telephone
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maintained.
A double-dummy design was used for retaining the
blinding (Supplementary File 3). UMEC/VI and correspond-
ing placebo were administered once-daily in the morning
via the ELLIPTA DPI. Blister packaged capsules of TIO or
its corresponding placebo were administered once daily in
the morning via the HandiHaler DPI.
The use of albuterol/salbutamol provided by
GlaxoSmithKline via metered dose inhaler as relief
medication was permitted throughout the study, but was
withheld for 4 h prior to spirometry testing. Inhaled
corticosteroids (ICS) at a consistent dose of up to
1000 mcg/day of fluticasone propionate or equivalent were
permitted and recorded. Systemic, oral, or parenteral
corticosteroids were prohibited within 6 weeks prior to Visit
1 (12 weeks for depot corticosteroids); ICS dose greater
than 1000 mcg/day was prohibited within 30 days of Visit 1.
Initiation or discontinuation of ICS within 30 days prior to
Visit 1 was not permitted. If a patient was being treated
with ICS at screening, it was to be continued to the end of
the treatment period unless there was a significant medical
reason for discontinuation. Use of combination LABA/ICS,
TIO, and LABA monotherapy was prohibited 30 days, 14
days, and 48 h prior to Visit 1, respectively. A full list of
prohibited medications and corresponding timeframes are
provided in Supplementary File 2.
Outcomes and assessments
The primary endpoint was trough forced expiratory volume
in 1 s (FEV1) at Day 169 (defined as mean of FEV1 values
obtained 23 and 24 h after the previous day’s dosing). The
secondary endpoint was weighted mean (WM) FEV1 over
0e6 h post-dose at Day 168. In addition, other lung function
endpoints assessed included trough FEV1 at Days 2, 28, 56,
84, 112, 140, and 168, WM FEV1 over 0e6 h post-dose at
Days 1 and 84, time to onset of action (defined as an in-
crease of 0.100 L above baseline in FEV1) during 0e6 h post-
dose at Day 1, trough forced vital capacity (FVC) at Day
169, percentage of responders achieving an increase in
FEV1 of 12% and 0.200 L above baseline at any time
during 0e6 h post-dose at Day 1, percentage of responders
achieving an increase in trough FEV1 of 0.100 L above
baseline at Day 169, peak FEV1 (maximum FEV1 recorded
over 0e6 h post-dose time points) at Day 168. Additional
efficacy outcomes are described in Supplementary File 4.
Incidence of adverse events (AEs) and AEs of special
interest (cardiovascular events, pneumonia, lower respira-
tory tract infection [LRTI]; Supplementary File 5) were
investigated during the treatment period.
Sample size and statistical analyses
Assuming a 2-sided 5% significance level and an estimate of
residual standard deviation for trough FEV1 of 0.240 L
(based on mixed models repeated measures [MMRM]
analysis of previous studies), a study with 337 evaluable
patients per arm would have 90% power to detect a 0.060 L
difference between treatments in trough FEV1. It was
estimated that approximately 25% of patients wouldwithdraw from the study without providing a Week 24/Day
169 assessment. Therefore, it was planned that 450
patients should be randomized to each treatment arm.
Primary analyses were performed on the intent-to-treat
(ITT) population, defined as all randomized patients who
had received at least one dose of study drug during the
treatment period. The primary endpoint, trough FEV1 at
Day 169 was analyzed using MMRM analysis [14], including
covariates of baseline FEV1, smoking status, Day, center
group, treatment, Day by baseline interaction, and Day by
treatment interaction, where Day is nominal. The model
used all available trough FEV1 values recorded at Days 2,
28, 56, 84, 112, 140, 168, and 169. Missing data were not
directly imputed in this analysis. However, all non-missing
data for a subject were used within the analysis to esti-
mate the treatment effect for trough FEV1 at Day 169. The
secondary endpoint, 0e6 h WM FEV1 was analyzed in a
similar fashion. See Supplementary File 6 for more details
on statistical analyses.
To account for multiplicity across treatment compari-
sons and key endpoints, a step-down closed testing proce-
dure was used. Accordingly, if the UMEC/VI 62.5/25 versus
TIO comparison for the primary efficacy endpoint of trough
FEV1 on Day 169 demonstrated statistical significance at the
5% level then the comparison of the secondary efficacy
endpoint (0e6 h WM FEV1) on Day 168 would be tested.
Likewise, inferences from all other comparisons with
respect to other efficacy endpoints were made if the
treatment comparison for the secondary efficacy endpoint
was statistically significant at the 5% level. No further
multiplicity adjustments were applied.
Exploratory analyses were performed to investigate if
the treatment effect on the primary and secondary
endpoint was modified by factors of interest. One such
factor of interest was ICS use at Screening (eg, present or
not present). This analysis was done by fitting a repeated
measures model that included the same covariates as in the
main analysis, with the addition of terms for ICS Use and ICS
Use by treatment interaction (see Supplementary File 6 for
additional details).
Results
Patients
The study took place between January 2013 and October
2013. In total, 1191 patients were enrolled in the study and
905 patients were randomized to receive treatment. All 905
patients were included in the ITT population (Fig. 1). The
overall subject disposition was similar for each treatment
group. Most patients completed the study (88%, UMEC/VI
group; 86%, TIO group). The most common reasons for
withdrawal were AEs, lack of efficacy, and withdrawn
consent (Fig. 1).
Patient demographics were similar between treatment
groups (Table 1). Approximately 50% of patients in
both treatment groups were taking ICS from 30 days prior to
Screening (Visit 1) to the end of the treatment period.
A greater percentage of patients were reversible to
salbutamol/ipratropium compared with those reversible to
salbutamol alone. Greater improvements in FEV1 were also
Figure 1 Patient flow. TIO, tiotropium bromide; UMEC, umeclidinium bromide; VI, vilanterol.
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salbutamol alone (Table 1).
Outcomes
Lung function
A clinically meaningful and statistically significant
improvement of 0.112 L (95% confidence interval [CI]:
0.081, 0.144) in trough FEV1 at Day 169 was observed for
UMEC/VI 62.5/25 mcg versus TIO 18 mcg (Table 2).Table 1 Patient demographics and characteristics (ITT populat
Age (Years), mean (SD)
Sex, n (%)
Male
Current smoker at screening,a n (%)
Smoking pack-years, mean (SD)
ICS use (pre-treatment), n (%)
Post-salbutamol percent predicted FEV1, mean (SD)
Post-salbutamol FEV1, L, mean, (SD)
Albuterol/salbutamol use (mean puffs/day), mean, (SD)
Post-salbutamol FEV1/FVC, mean (SD)
GOLD stage, n (%)
II
III
IV
Reversibility to salbutamol,
L, mean, (SD)
Reversible to salbutamol,b n (%)
Reversibility to salbutamol and ipratropium,
L, mean, (SD)
Reversible to salbutamol and ipratropium,c n (%)
FEV1, forced expiratory volume in 1 second; FVC, forced vital capac
corticosteroids; ITT, intent-to-treat; SD, standard deviation; TIO, tiot
a Patients were classed as current smokers if they had smoked with
b Patients are reversible to salbutamol if they have an increase in FE
c Patients are reversible to salbutamol and ipratropium if they have a
of both salbutamol and ipratropium.In addition, a clinically meaningful and statistically
significant improvement of 0.105 L (95% CI: 0.071, 0.140)
in 0e6 h WM FEV1 at Day 168 was also observed for
UMEC/VI 62.5/25 mcg versus TIO 18 mcg. Statistically
significant improvements for UMEC/VI 62.5/25 mcg versus
TIO were also observed early for both trough FEV1 and WM
FEV1, and were maintained at other clinic visits throughout
the study (Figs. 2 and 3, Supplementary Files 7 and 8).
The exploratory analyses suggested that there was no
impact of ICS use on treatment effect for trough FEV1 ation).
UMEC/VI 62.5/25 (N Z 454) TIO (N Z 451)
61.9 (8.41) 62.7 (8.50)
310 (68) 303 (67)
270 (59) 243 (54)
44.1 (24.44) 44.4 (25.03)
247 (54) 237 (53)
46.2 (13.02) 46.5 (12.76)
1.41 (0.4854) 1.41 (0.5036)
3.3 (3.37) 3.2 (3.16)
47.82 (10.78) 47.40 (10.92)
185 (41) 190 (42)
207 (46) 206 (46)
62 (14) 55 (12)
0.15 (0.150) 0.15 (0.155)
124 (27) 142 (31)
N Z 452 N Z 449
0.25 (0.199) 0.25 (0.203)
244 (54) 239 (53)
ity; GOLD, global initiative for chronic lung disease; ICS, inhaled
ropium bromide; UMEC, umeclidinium bromide; VI, vilanterol.
in 6 months of the screening visit.
V1 of 12% and 200 mL following administration of salbutamol.
n increase in FEV1 of 12% and 200 mL following administration
Table 2 Lung function measures (ITT population).
UMEC/VI 62.5/25 (N Z 454) TIO (N Z 451)
Primary endpoint: trough FEV1 at Day 169, L
LS mean change from baseline (SE) 0.205 (0.0114) 0.093 (0.0115)
Treatment difference (95% CI)
UMEC/VI 62.5/25 versus TIO 0.112 (0.081, 0.144)
p-value <0.001
Secondary endpoint: 0e6 h WM FEV1 at Day 168, L
LS mean change from baseline (SE) 0.276 (0.0124) 0.170 (0.0126)
Treatment difference (95% CI)
UMEC/VI 62.5/25 versus TIO 0.105 (0.071, 0.140)
p-value <0.001
Other lung function measures
Time to onset at Day 1
Median time to onseta (min) 19 31
HR (95% CI)
UMEC/VI 62.5/25 versus TIO 1.34 (1.16, 1.55)
p-value <0.001
Trough FVC (L) at Day 169, L
LS mean change from baseline (SE) 0.244 (0.0181) 0.120 (0.0183)
Treatment difference (95% CI)
UMEC/VI 62.5/25 versus TIO 0.124 (0.073, 0.174)
p-value <0.001
Patients achieving increase in FEV1 of ‡12% and ‡0.200 L above
baseline at any time during 0e6 h post-dose at Day 1
290 (64) 223 (49)
Increase, n (%)
OR (95% CI)
UMEC/VI 62.5/25 versus TIO 1.8 (1.4, 2.4)
p-value <0.001
Patients achieving an increase in trough FEV1 of ‡0.100 L above baseline at Day 169
Increase, n (%) 275 (61) 192 (43)
OR (95% CI)
UMEC/VI 62.5/25 versus TIO 2.1 (1.6, 2.7)
p-value <0.001
Peak FEV1 at Day 168, L
LS mean change from baseline (SE) 0.351 (0.0131) 0.255 (0.0133)
Treatment difference, (95% CI)
UMEC/VI 62.5/25 versus TIO 0.095 (0.059, 0.132)
p-value <0.001
CI, confidence interval; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; HR, hazard ratio; ITT, intent-to-treat;
LS, least squares; OR, odds ratio; SE, standard error; TIO, tiotropium bromide; UMEC, umeclidinium bromide; VI, vilanterol;
WM, weighted mean.
a Kaplan-Meier estimate.
1756 M.R. Maleki-Yazdi et al.Day 169 and 0e6 h WM FEV1 at Day 168. Further details of
the exploratory analyses of other factors of interest can be
found in Supplementary File 9.
Median time to onset of action defined as a post-dose
FEV1 0.100 L above baseline, during the 0e6 h post-dose
on Day 1 was shorter in UMEC/VI 62.5/25 mcg versus
TIO 18 mcg (19 versus 31 min: Table 2). The proportion of
patients experiencing: i) an increase in FEV1 of 12% and
0.200 L above baseline 0e6 h post-dose on Day 1; and
ii) an increase in trough FEV1 of 0.100 L above baseline at
Day 169, was greater with UMEC/VI 62.5/25 mcg versus
TIO 18 mcg for both thresholds (Table 2). Similarly,
patients receiving UMEC/VI 62.5/25 mcg had statistically
significantly higher odds of achieving both thresholdsversus TIO 18 mcg (Table 2). Statistically significant
improvements in peak FEV1 on Day 168 were observed for
UMEC/VI 62.5/25 mcg versus TIO 18 mcg (Table 2).
For trough FVC at Day 169, a statistically significant and
clinically meaningful improvement was observed with
UMEC/VI 62.5/25 versus TIO 18 mcg (0.124 L [95% CI: 0.073,
0.174]; Table 2). Improvements in FVC were also observed
at Day 2 and maintained at other clinic visits in the study
(Fig. 4, Supplementary File 10).
Other efficacy outcomes
A small percentage of patients in each group reported
an on-treatment COPD exacerbation (Supplementary
File 11).
Figure 2 LS mean change from baseline in trough FEV1, L
(ITT population). CI, confidence interval; FEV1, forced expira-
tory volume in 1 s; ITT, intent-to-treat; LS, least squares; TIO,
tiotropium bromide; UMEC, umeclidinium bromide; VI,
vilanterol.
Figure 4 LS mean change from baseline in trough FVC (L)
(ITT population). CI, confidence interval; FVC, forced vital
capacity; ITT, intent-to-treat; LS, least squares; TIO, tio-
tropium; UMEC, umeclidinium bromide; VI, vilanterol. Analysis
performed using a repeated measures model with covariates of
treatment, baseline (mean of the two FVC assessments made
30 and 5 min pre-dose on Day 1), smoking status, center group,
Day, Day by baseline, and Day by treatment interactions. Day
axis is not to scale.
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Statistically significant improvements in St George’s Respi-
ratory Questionnaire (SGRQ) total score were observed for
the UMEC/VI 62.5/25 mcg group versus TIO 18 mcg at Day
28, 84, and 168 (Table 3, Fig. 5, Supplementary File 12).
The proportion of SGRQ responders at Day 28 and 84 and
SGRQ domain scores at Day 168 are summarized in
Supplementary Files 13 and 14, respectively.
Rescue use
A statistically significant reduction from baseline in rescue
salbutamol use over 24 weeks was observed with
UMEC/VI 62.5/25 mcg versus TIO 18 mcg (Table 3).Safety and tolerability
The overall incidence of on-treatment AEs was similar in
both treatment groups (44% UMEC/VI group versus 42%, TIO
group) (Table 4).Figure 3 LS mean change from baseline in 0e6 h WM FEV1
(ITT population). CI, confidence interval; FEV1, forced expira-
tory volume in 1 s; h, hours; ITT, intent-to-treat; LS, least
squares; TIO, tiotropium bromide; UMEC, umeclidinium bro-
mide; VI, vilanterol; WM, weighted mean.The incidence of on-treatment SAEs was low (4% for
both treatment groups), and no on-treatment SAEs were
considered related to study drug (Table 4).
Seven deaths occurred during the study comprising two
subjects in the UMEC/VI treatment group (cardiac failure
and death from unknown reason) and five subjects in the
TIO group (sudden death, pancreatic carcinoma, respira-
tory failure, pulmonary embolism, and cardiac failure
acute). None of the deaths were judged to be related to the
study drug.
The incidence of any cardiovascular AEs of special in-
terest was equivalent between UMEC/VI 62.5/25 mcg (2%)
and TIO 18 mcg (2%). Incidence of pneumonia and LRTI
was also similar between UMEC/VI 62.5/25 mcg (<1%)
and TIO 18 mcg (1%) (Table 4). The subject in the
UMEC/VI 62.5/25 group with an on-treatment pneumonia
event had entered screening on an ICS. Of the three TIO
subjects that had an on-treatment pneumonia event, one
subject was receiving an ICS.
Discussion
The patient population in this study consisted of patients
with COPD who had moderate-to-very severe disease and
characteristics similar to other studies of LAMAs and LABAs
[10,11,15]. Results from this study demonstrated statisti-
cally significant and clinically meaningful improvements
with UMEC/VI 62.5/25 mcg on trough FEV1 at Day 169 and
WM FEV1 over 0e6 h post-dose at Day 168 versus
TIO 18 mcg. This suggests that UMEC/VI was a more
effective bronchodilator than TIO at the beginning and end
of the dosing interval. The improvements in trough FEV1
and WM FEV1 were consistent over the 24-week study, and
are in line with previous studies of UMEC/VI versus TIO [12].
Table 3 HRQoL (SGRQ scores) and rescue use (ITT population).
UMEC/VI 62.5/25
(N Z 454)
TIO (N Z 451)
SGRQ total score at Day 168, LS mean change from baseline (SE) 7.27 (0.538) 5.17 (0.548)
Treatment difference (95% CI) 2.10 (3.61, 0.59)
UMEC/VI 62.5/25 versus TIO 0.006
p-value
Proportion of SGRQ responders at Day 168
Responder, n (%) 237 (53) 196 (46)
Treatment difference, OR (95% CI)
UMEC/VI 62.5/25 versus TIO 1.4 (1.0, 1.8)
p-value 0.022
Rescue albuterol/salbutamol use (mean puffs/day over Weeks 1e24), 1.3 (0.09) 0.8 (0.09)
LS mean change from baseline (SE)
Treatment difference, (95% CI)
UMEC/VI 62.5/25 versus TIO 0.5 (0.7, 0.2)
p-value <0.001
CI, confidence interval; HRQoL, health-related quality of life; ITT, intent-to-treat; LS, least squares; OR, odds ratio; SGRQ, St George’s
respiratory questionnaire; SE, standard error; TIO, tiotropium bromide; UMEC, umeclidinium bromide; VI, vilanterol.
The odds of being a responder (defined as a reduction from baseline in SGRQ total score of 4 units) were statistically significantly
greater for UMEC/VI 62.5/25 mcg versus TIO 18 mcg at Day 28, 84, and 168 (Table 3, Supplementary File 12).
Table 4 Summary of adverse events (ITT population).
UMEC/VI
62.5/25
(N Z 454)
TIO
(N Z 451)
Any on-treatment AEs, n (%) 202 (44) 190 (42)
Most common on-treatment AEs
(reported in 3% patients
1758 M.R. Maleki-Yazdi et al.Evidence of improvement in QoL with UMEC/VI was
observed, with UMEC/VI demonstrating statistically signifi-
cant improvements in the SGRQ score (a respiratory-related
QoL measure) versus TIO, which was further supported by
significant reductions in rescue medication use.
Permitted concurrent medications for the duration of
the study from screening through to the end of the treat-
ment period included ICS up to a maximum daily dose of
1000 mcg fluticasone propionate or equivalent. An explor-
atory analysis suggested that ICS use did not impact the
treatment effect on trough FEV1 at Day 169. There are
limitations to this analysis, including that the study was
not powered to detect interactions and treatmentFigure 5 LS mean (96% CI) change from baseline in SGRQ
total score (ITT population). CI, confidence interval; ITT,
intent-to-treat; LS, least squares; SGRQ, St George’s Respira-
tory Questionnaire; TIO, tiotropium; UMEC, umeclidinium
bromide; VI, vilanterol. Analysis performed using a repeated
measures model with covariates of treatment, baseline (score
on Day 1), smoking status, center group, Day, Day by baseline,
and Day by treatment interactions.randomization was not stratified by ICS use. However, it
should be noted that in a pre-specified subgroup analysis
conducted using integrated data (N Z 4713; ITT popula-
tion) from four 24-week, multicenter, randomized, double-in any treatment group, n (%)
Headache 40 (9) 31 (7)
Nasopharyngitis 28 (6) 30 (7)
Cough 13 (3) 15 (3)
Back pain 9 (2) 13 (3)
Any on-treatment SAEs, n (%) 16 (4) 17 (4)
Any drug-related AEs, n (%) 19 (4) 17 (4)
Any AEs related to permanent
discontinuation of
medication/withdrawal, n (%)
18 (4) 14 (3)
Fatal AEs, n (%)
Any on-treatment fatal AEs 2 (<1) 2 (<1)
Any post-treatment fatal AEs 0 3 (<1)
On-treatment AEs of special interest, n (%)
Cardiovascular e any event 9 (2) 7 (2)
Cardiac arrhythmias 3 (<1) 4 (<1)
Cardiac failure 4 (<1) 3 (<1)
Cardiac ischemia 2 (<1) 3 (<1)
Stroke 0 0
Pneumonia and LRTI e any event 4 (<1) 6 (1)
LRTI excluding pneumonia 3 (<1) 3 (<1)
Pneumonia 1 (<1) 3 (<1)
AE, adverse event; ITT, intent-to-treat; LRTI, lower respiratory
tract infection; SAE, serious AE; TIO, tiotropium bromide;
UMEC, umeclidinium bromide; VI, vilanterol.
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patients with COPD, UMEC/VI at doses of 125/25 mcg and
62.5/25 mcg demonstrated similar magnitudes of
improvement in trough FEV1 at Day 169 compared with
placebo in the subgroups of ICS users and non-ICS users
[16].
These results add to a growing body of evidence
supporting the use of dual bronchodilator therapy over
bronchodilator monotherapy in the management of
symptomatic patients with COPD. Early studies showed that
the free combination of TIO and formoterol produced
greater improvements in day-time and night-time FEV1 than
either component in patients with COPD [6]. More recently,
the SHINE study (ClinicalTrials.gov: NCT01202188; in
patients with moderate-to-very severe COPD) demon-
strated that the fixed-dose LAMA/LABA combination
QVA149 (glycopyrronium/indacaterol; Novartis Pharma-
ceuticals) produced statistically significant improvements
in trough FEV1 after 26 weeks, in comparison with indaca-
terol, glycopyrronium, TIO, and placebo [17]. A fixed-dose
combination of aclidinium bromide/formoterol fumarate
(Almirall and Forest Laboratories) is also in development,
with a large clinical trial program underway in patients with
moderate-to-severe COPD [18].
UMEC/VI 62.5/25 mcg was well tolerated in the present
study, and had a safety profile similar to that of TIO. There
was a similar overall incidence of AEs in each study group,
and a low incidence of SAEs. Both muscarinic antagonists
and b2-agonists have previously been associated with
adverse effects on the cardiovascular system [19,20], and
therefore incidence of these effects were considered to
be of interest in this study. Overall, the incidence of
cardiovascular AEs of special interest was low: 2% for both
UMEC/VI and TIO. Pneumonia is a common event in the
COPD population [21,22]. In this study, the incidence of
pneumonia and LRTIs was low in both the UMEC/VI (<1%)
and TIO (1%) treatment groups, despite >50% of patients
receiving ICS.
Current COPD treatment guidelines recommend a combi-
nation of a LAMA/LABA as an option for patients with
significant symptoms and a low risk of exacerbations,
patients with few symptoms and a high risk of exacerbations,
and patients with many symptoms and high risk of
exacerbations [2]. Additional studies of LABA/LAMA combi-
nations in patients with differing severities of COPD, as well
as in combination with ICS, would be useful to expand the
experiencewithUMEC/VI, further characterize thebenefit of
this combination in clinical practice, and help determine its
optimal place in the treatment paradigm of COPD.Conclusions
The results of the present study demonstrated statistically
significant and clinically meaningful improvements in
trough FEV1 for UMEC/VI versus TIO, which was supported
by a clinically meaningful improvement in 0e6 h WM FEV1.
Improvements were also observed in measures considered
important to patients, including rescue medication use and
HRQoL. Overall, UMEC/VI was well tolerated. These find-
ings show that UMEC/VI 62.5/25 mcg could provide an
effective new treatment option for patients withmoderate-to-very severe COPD, providing greater efficacy
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